BAT FY2025 Results: New Categories Contribution Expands as Smokeless Share Reaches 18.2%

Feb.12
BAT FY2025 Results: New Categories Contribution Expands as Smokeless Share Reaches 18.2%
British American Tobacco reported FY2025 revenue of £25.61 billion, down 1.0% on a reported basis but up 2.1% at constant currency. New Categories revenue rose 5.5%, with category contribution increasing 77%. Smokeless products accounted for 18.2% of group revenue.

Key Points

 

  • Revenue: £25,610m (≈ USD 33.78bn)
  • Reported change: -1.0%
  • Constant currency growth: +2.1%
  • Operating Profit: £9,997m (≈ USD 13.18bn)
  • Adjusted Operating Profit: £11,572m
  • Diluted EPS: 349.1p
  • Dividend per Share: 245.04p (+2.0%)
  • New Categories Revenue: £3,621m (≈ USD 4.78bn)
  • New Categories Category Contribution: £427m
  • Smokeless Revenue Share: 18.2%
  • Smokeless Consumers: 34.1 million

 

USD conversions are based on the FY2025 average exchange rate disclosed by the company (1 GBP = 1.319 USD).

 


 

2Firsts, February 12, 2026

 

British American Tobacco (BAT) on Thursday afternoon reported full-year 2025 revenue of £25.61 billion, equivalent to approximately USD 33.78 billion based on the company’s disclosed 2025 average exchange rate of 1 GBP = 1.319 USD. Revenue declined 1.0% on a reported basis but increased 2.1% at constant exchange rates.

 

Profit from operations reached £9.997 billion (approximately USD 13.18 billion). The reported increase reflects the prior-year impairment base effect. Adjusted operating profit rose modestly on a constant currency basis. Adjusted diluted earnings per share increased 0.7% at constant rates, while dividend per share rose 2.0% to 245.04 pence.

 

New Categories—comprising vapour, heated products and modern oral—generated £3.62 billion (approximately USD 4.78 billion) in revenue, up 5.5% on a reported basis and 7.0% at constant currency. Category contribution increased 77.1% to £427 million, with margin expanding to 11.8%.

 

Modern Oral revenue reached £1.17 billion, growing 47.4% on a reported basis. Vapour revenue declined 10.4%, while heated products were broadly stable year-on-year on a reported basis and increased slightly at constant currency.

 

BAT FY2025 Results: New Categories Contribution Expands as Smokeless Share Reaches 18.2%
Figure 1: BAT presentation showing Velo’s volume share progression in the U.S. modern oral nicotine category. The slide indicates continued share gains following the launch of Velo Plus in November 2024, with the brand reaching the No.2 volume and value share position in the U.S. in Q4 2025. Operational metrics including price index, trial conversion and state-level share are also highlighted. | Source: BAT, Preliminary Results 2025 Presentation, February 12, 2026.

 

Smokeless products accounted for 18.2% of group revenue, an increase of 70 basis points. Smokeless consumers totaled 34.1 million, up 4.7 million year-on-year.

 

Combustibles revenue totaled £20.20 billion, down 2.3% on a reported basis but up 1.0% at constant exchange rates.

 

BAT stated that New Categories returned to double-digit growth in the second half of the year, supported by performance in modern oral and recent premium launches including Vuse Ultra, glo Hilo and Velo Shift.

 

Further coverage and analysis will follow from 2Firsts.

 

Cover image: BAT, Preliminary Results 2025 Presentation, February 12, 2026.


BAT FY2025 Results: New Categories Contribution Expands as Smokeless Share Reaches 18.2%
Al Fakher Parent AIR Advances U.S. Listing Plan, With Deal Expected in First Half of 2026
Al Fakher Parent AIR Advances U.S. Listing Plan, With Deal Expected in First Half of 2026
AIR Limited and Cantor Equity Partners III, Inc. announced that AIR and AIR Holdings Limited have filed a Form F-4 registration statement with the U.S. Securities and Exchange Commission in connection with their previously announced proposed business combination. Upon closing, the combined company, AIR Global PLC, is expected to be listed on Nasdaq in the United States under the ticker symbol “AIIR.”
Mar.31 by 2FIRSTS.ai
EVO NXT 2026 Opens in Prague as Global NGP Industry Gathers for Two-Day Event
EVO NXT 2026 Opens in Prague as Global NGP Industry Gathers for Two-Day Event
2026 — EVO NXT 2026 officially opened today in Prague, bringing together manufacturers, brand owners, retailers, and decision-makers from across the global next-generation products (NGP) industry. As the event’s official media partner for the fourth consecutive year, 2Firsts is reporting on site, tracking key developments across the exhibition floor, forum agenda, and broader industry discussions.
Apr.17 by 2FIRSTS.ai
Special Report | PLONQ Expands in China With New Shenzhen Hub to Accelerate R&D and Partnerships
Special Report | PLONQ Expands in China With New Shenzhen Hub to Accelerate R&D and Partnerships
On March 27, 2026, PLONQ officially opened its upgraded Shenzhen office, reinforcing its long-term commitment to China and marking a new phase of growth. As a leading vape brand in Russia, PLONQ is expanding into new product categories while strengthening R&D, engineering collaboration, and partnerships with Chinese companies. The Shenzhen office will accelerate product development, enhance cooperation with technology and manufacturing partners, and support future growth initiatives.
Apr.01
KT&G Q1 2026 Financial Results: Revenue at $1.156 Billion, E-Cigarettes to Launch Independent Overseas Expansion
KT&G Q1 2026 Financial Results: Revenue at $1.156 Billion, E-Cigarettes to Launch Independent Overseas Expansion
KT&G reports a 27.6% increase in Q1 operating profit, with traditional and new tobacco sectors driving growth.
May.07 by 2FIRSTS.ai
FDA Filing Shows RIF Notices for 229 CTP Employees Were Largely Rescinded
FDA Filing Shows RIF Notices for 229 CTP Employees Were Largely Rescinded
A court declaration signed by FDA official Melanie M. Keller on March 24, 2026 detailed the status of previously issued reduction-in-force notices affecting employees at the Center for Tobacco Products (CTP).
Apr.01 by 2FIRSTS.ai
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Summary Ispire Technology announced a strategic joint venture with Chinese pharmaceutical company Jincheng Pharma to manufacture and commercialize nicotine pouch products. The partnership combines pharmaceutical-grade production capabilities with Ispire’s global regulatory infrastructure and distribution network as the company expands beyond vaping hardware into oral nicotine products.
Business
May.13